1. Paraneoplastic Sensory Polyneuropathy Related to Anti-PD-L1-including Anticancer Treatment in a Patient with Lung Cancer.
- Author
-
Morimoto T, Orihashi T, Yamasaki K, Tahara M, Kato K, and Yatera K
- Subjects
- Autoantibodies, Carboplatin adverse effects, Humans, Lung Neoplasms drug therapy, Paraneoplastic Polyneuropathy chemically induced, Paraneoplastic Polyneuropathy diagnosis, Small Cell Lung Carcinoma complications, Small Cell Lung Carcinoma drug therapy
- Abstract
Paraneoplastic neurological syndromes (PNS), such as sensory polyneuropathy, are rare, and serum neuronal antibodies that are used for diagnosing this syndrome are occasionally positive. Similarly, neurological immune-related adverse events due to immune checkpoint inhibitors (ICIs) are also rare. However, their etiologies and the relationship between them remain unclear. We herein report a patient with suspected small cell lung cancer who showed sensory polyneuropathy after treatment with atezolizumab in combination with cytotoxic agents (carboplatin and etoposide) and was doubly positive for serum anti-Hu and anti-SOX-1 antibodies. Treatment with ICI and cytotoxic agents may sometimes lead to the development of PNS.
- Published
- 2021
- Full Text
- View/download PDF